ZURICH (Reuters) – Swiss drugmaker Roche on Tuesday won approval in Japan for Rozlytrek as the world’s biggest maker of cancer drugs pushes ahead in personalized medicines that require a biomarker test to identify prospective patients.
Roche said Japan is the first country to approve Rozlytrek, also known as entrectinib, targeting people with NTRK fusion-positive solid tumors, across 10 different tumor types, including those with central nervous system metastases.
0 comments
Share
